Reltecimod TFA
Description
Reltecimod (AB-103) TFA is an antagonist of the T cell-specific surface glycoprotein CD28 (TP44). Reltecimod TFA has good resistance effects against different bacterial infections, bacterial exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates inflammatory responses by targeting and attenuating, but not inhibiting, the critical CD28/B7-2 costimulatory pathway. Reltecimod TFA can be used in research on necrotizing soft tissue infections (NSTIs).
Product Details
| Product Name | Reltecimod TFA |
| Biological activity | Reltecimod (AB-103) TFA is a T-cell-specific surface glycoprotein CD28 (TP44) antagonist. Reltecimod TFA has beneficial effects against different bacterial infections, their exotoxins and endotoxins, and ionizing radiation. Reltecimod TFA modulates the inflammatory response by targeting and attenuating the critical CD28/B7-2 co-stimulatory pathway, without inhibiting it. Reltecimod TFA can be used to research necrotizing soft-tissue infections (NSTIs). |
| Formula | C46H72N10O15S.xC2HF3O2 |
| Appearance | Solid |
| Color | White to off-white |
| Sequence | {d-Ala}-Ser-Pro-Met-Leu-Val-Ala-Tyr-Asp-{d-Ala} |
| Sequence Shortening | {d-Ala}-SPMLVAYD-{d-Ala} |
| Storage | Sealed storage, away from moisture and light |
